Confounding by drug formulary restriction in pharmacoepidemiologic research

Pharmacoepidemiology and Drug Safety

Volumn 25, Issue 3, 2016, Pages 278-286

  Filion, Kristian B ^a,b   Eberg, Maria ^a   Ernst, Pierre ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Bias; Confounding; Drug formulary restrictions; Pharmacoepidemiology

Indexed keywords

FLUTICASONE; SALMETEROL; BRONCHODILATING AGENT; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE;

ADULT; ARTICLE; ASTHMA; CANADA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; DRUG FORMULARY; FEMALE; HAZARD RATIO; HOSPITALIZATION; HUMAN; INHALER; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHARMACOEPIDEMIOLOGY; PNEUMONIA; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; DRUG UTILIZATION REVIEW; EPIDEMIOLOGY; FACTUAL DATABASE; OUTCOME ASSESSMENT; PROCEDURES; PUBLICATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUEBEC; RETROSPECTIVE STUDY; STANDARDS; STATISTICS AND NUMERICAL DATA; TRENDS;

ASTHMA; BRONCHODILATOR AGENTS; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DATABASES, FACTUAL; DRUG UTILIZATION REVIEW; FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE DRUG COMBINATION; FORMULARIES AS TOPIC; HOSPITALIZATION; HUMANS; MORTALITY; OUTCOME ASSESSMENT (HEALTH CARE); PHARMACOEPIDEMIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUEBEC; RETROSPECTIVE STUDIES;

EID: 84959552208     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3923     Document Type: Article

References (18)

1. Blais L, Ernst P, Suissa S. Confounding by indication and channeling over time: the risks of beta 2-agonists. Am J Epidemiol 1996; 144(12): 1161-1169.
2. Joffe MM. Confounding by indication: the case of calcium channel blockers. Pharmacoepidemiol Drug Saf 2000; 9(1): 37-41.
3. Huybrechts KF, Brookhart MA, Rothman KJ, et al. Comparison of different approaches to confounding adjustment in a study on the association of antipsychotic medication with mortality in older nursing home patients. Am J Epidemiol 2011; 174(9): 1089-1099.
4. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiol 2009; 20(4): 512-522.
5. Klungel OH, Martens EP, Psaty BM, et al. Methods to assess intended effects of drug treatment in observational studies are reviewed. J Clin Epidemiol 2004; 57(12): 1223-1231.
6. McMahon AD. Approaches to combat with confounding by indication in observational studies of intended drug effects. Pharmacoepidemiol Drug Saf 2003; 12(7): 551-558.
7. Gamble JM, McAlister FA, Johnson JA, Eurich DT. Restrictive drug coverage policies can induce substantial drug exposure misclassification in pharmacoepidemiologic studies. Clin Ther 2012; 34(6): 1379-1386.
8. Gamble JM, McAlister FA, Johnson JA, Eurich DT. Quantifying the impact of drug exposure misclassification due to restrictive drug coverage in administrative databases: a simulation cohort study. Value Health 2012; 15(1): 191-197.
9. Saad N, Camus P, Suissa S, Ernst P. Statins and the risk of interstitial lung disease: a cohort study. Thorax 2013; 68(4): 361-364.
10. Lapi F, Kezouh A, Suissa S, Ernst P. The use of inhaled corticosteroids and the risk of adrenal insufficiency. Eur Respir J 2013; 42(1): 79-86.
11. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158(9): 915-920.
12. Régie de l'assurance maladie du Québec. Systeme respiratoire. 2015; http://www.ramq.gouv.qc.ca/SiteCollectionDocuments/professionnels/medicaments/codes-medicaments-exception/RE.pdf. Accessed 03/03/2015.
13. Skull SA, Andrews RM, Byrnes GB, et al. ICD-10 codes are a valid tool for identification of pneumonia in hospitalized patients aged > or =65years. Epidemiol Infect 2008; 136(2): 232-240.
14. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993; 46(10): 1075-1079.
15. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43(11): 1130-1139.
16. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001; 154(9): 854-864.
17. Guertin J, LeLorier J, Durand M, Gow R, Holbrook A, Levine M. Impact of a restrictive drug access program on the risk of cardiovascular encounters in children exposed to ADHD medications. J Popul Ther Clin Pharmacol 2014; 21(3): e357-369.
18. Filion KB, Chateau D, Targownik LE, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut 2014; 63(4): 552-558.